Sermorelin Post-COVID / Long-COVID Recovery Protocol

What Is Sermorelin and Why Does It Matter for Long-COVID?

Sermorelin is the first 29 amino acids of endogenous GHRH, the hypothalamic signal that triggers the pituitary to release GH in pulses. Unlike direct GH injections, it works through the native feedback axis, which caps IGF-1 within physiological range and makes dose-related side effects easier to manage.

Long-COVID (formally Post-Acute Sequelae of SARS-CoV-2 Infection, or PASC) affects an estimated 10 to 20% of people who had acute COVID-19, according to a 2023 CDC analysis covering more than 1.8 million patient records [1]. Cardinal symptoms include debilitating fatigue, post-exertional malaise, cognitive slowing, disordered sleep, and slow immune normalization. Each of these domains has mechanistic overlap with GH axis suppression.

The GH Axis in PASC: Why Suppression Happens

SARS-CoV-2 infection triggers a prolonged pro-inflammatory state. Elevated interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) suppress hypothalamic GHRH secretion and reduce pituitary GH pulse amplitude [2]. Cortisol, which remains chronically elevated in a subset of long-COVID patients, further blunts the axis. A 2021 paper in the Journal of Clinical Endocrinology and Metabolism documented pituitary changes in a cohort of hospitalized COVID-19 survivors, with 6.4% showing biochemical GH deficiency at 3-month follow-up [3].

The result is a state of functional GH insufficiency even in adults who had normal GH secretion before infection. Sleep disruption compounds this. Most physiological GH pulsatility occurs in slow-wave sleep; fragmented sleep architecture, a near-universal PASC complaint, further reduces GH output over a 24-hour period.

How GH Insufficiency Drives Long-COVID Symptoms

Low IGF-1 has direct consequences across all the major PASC symptom clusters:

• Fatigue and mitochondrial dysfunction. IGF-1 regulates mitochondrial biogenesis through the PI3K/Akt/mTOR pathway. A 2022 review in Frontiers in Physiology showed that reduced IGF-1 signaling correlates with decreased mitochondrial complex I and IV activity [4], matching the patterns seen in PASC muscle biopsies.
• Cognitive fog. GH receptors are expressed throughout the hippocampus and prefrontal cortex. A 2020 meta-analysis of 22 studies (N=801 adults with GH deficiency) found that GH replacement improved visual memory and processing speed scores by a standardized mean difference of 0.40 (P<0.01) [5].
• Immune dysregulation. IGF-1 promotes thymic T-cell maturation and natural killer cell activity. Persistently low IGF-1 may slow the immune reconstitution that PASC patients need.

Sermorelin Protocol for Post-COVID Recovery

This protocol reflects current compounding-pharmacy practice and published GHRH analogue literature. No randomized controlled trial has tested sermorelin specifically in a PASC population as of mid-2025. Evidence level designations are provided for each recommendation.

Baseline Evaluation Before Starting

Confirm the following before prescribing:

1. IGF-1 (serum). Establishes the degree of GH axis suppression. Target the age- and sex-adjusted reference range; most labs use roughly 100 to 300 ng/mL for adults aged 30 to 60.
2. Fasting glucose and HbA1c. GH stimulation mildly antagonizes insulin. Patients with HbA1c above 6.5% need closer glucose monitoring [6].
3. Cortisol (8 AM). Elevated cortisol dampens GH pulse and may predict poor sermorelin response.
4. Thyroid panel (TSH, free T4). Hypothyroidism blunts GH secretion independent of the peptide.
5. PASC symptom scoring. Use a validated tool such as the PROMIS Fatigue Short Form or the PHQ-9 for mood; the WHO-5 Well-Being Index works well as a serial outcome tracker.
6. Contraindication screen. Rule out active or recent malignancy, uncontrolled diabetes (HbA1c >9%), intracranial pathology, and pregnancy.

Dosing and Administration

| Phase | Dose | Frequency | Duration | |---|---|---|---| | Induction | 200 mcg SQ at bedtime | Daily | Weeks 1 to 4 | | Titration | 300 to 500 mcg SQ at bedtime | Daily | Weeks 5 to 12 | | Maintenance | Lowest effective dose (usually 200 to 300 mcg) | 5 days on / 2 days off | Months 4 to 6+ |

Route. Subcutaneous injection using a 29 to 31 gauge, 5/16-inch insulin syringe. Rotate sites: abdomen, outer thigh, and deltoid subcutaneous fat. Reconstituted peptide (bacteriostatic water) stores at 2 to 8°C for up to 30 days.

Timing. Bedtime administration aligns with the natural GH pulse that peaks 1 to 2 hours after sleep onset, amplifying the physiological signal rather than overriding it [7].

Why start low. Beginning at 200 mcg minimizes water retention, flushing, and injection-site discomfort while allowing IGF-1 response assessment before titration.

The HealthRX Long-COVID GH Axis Recovery Framework stratifies patients at baseline by their IGF-1 z-score and cortisol burden, then selects between three pathways: sermorelin monotherapy (IGF-1 mildly low, cortisol normal), sermorelin plus low-dose DHEA (IGF-1 mildly low, cortisol elevated), or sermorelin combined with CJC-1295/Ipamorelin for faster IGF-1 normalization (IGF-1 severely suppressed, z-score below -2.0).

Combination Considerations

Some clinicians pair sermorelin with CJC-1295 (a longer-acting GHRH analogue) or ipamorelin (a selective GH secretagogue) to sustain IGF-1 elevation between sermorelin's short half-life pulses. Sermorelin's plasma half-life is approximately 10 to 20 minutes [8]; CJC-1295 without DAC extends GHRH receptor stimulation to 6 to 8 hours, making it a rational pharmacokinetic complement. That combination is widely used in anti-aging practice but carries the same lack of PASC-specific trial data.

Monitoring Schedule and Lab Targets

Labs at Each Timepoint

| Timepoint | Labs | |---|---| | Baseline | IGF-1, fasting glucose, HbA1c, TSH, free T4, 8 AM cortisol, CBC, CMP | | Week 6 to 8 | IGF-1, fasting glucose | | Week 12 to 16 | IGF-1, HbA1c, TSH, fasting glucose | | Month 6 | Full repeat of baseline panel plus PASC symptom scores |

IGF-1 target. Aim for the upper half of the age-adjusted normal range, not supraphysiological levels. Exceeding the normal ceiling (typically >300 ng/mL in most adults under 60) signals overtreatment; reduce dose by 100 mcg increments.

Glucose tolerance. GH stimulation can raise fasting glucose by 5 to 15 mg/dL. A 2019 safety review of GHRH analogues in adults aged 60 to 80 (N=137) found no statistically significant change in HbA1c over 6 months at doses up to 2 mg/day [9]. Patients with pre-diabetes should still have glucose checked at 6 to 8 weeks.

Symptom Outcome Tracking

Pair lab monitoring with patient-reported outcome measures every 4 to 6 weeks:

• PROMIS Fatigue Short Form 6a (score 0 to 40; PASC patients typically present at 28 to 36)
• Brief cognitive screen (Montreal Cognitive Assessment or Cogstate) at baseline and month 3
• Pittsburgh Sleep Quality Index for sleep architecture tracking
• PASC Global Health Rating (1 to 10 self-report)

A clinically meaningful fatigue response is generally defined as a 5-point reduction on the PROMIS Fatigue scale, consistent with thresholds used in NIH-funded PASC trials [10].

Expected Timeline of Outcomes

Realistic expectations reduce dropout and improve adherence. Based on published GHRH analogue literature and practitioner observational data, the likely sequence is:

Weeks 1 to 4: Sleep and Recovery First

Most patients notice improved sleep depth before any other change. This makes biological sense; deeper slow-wave sleep itself increases GH pulsatility, creating a positive feedback loop. Injection-site redness and mild morning drowsiness are common and generally resolve by week 3.

Weeks 4 to 8: Energy and Cognitive Lifting

IGF-1 begins to rise into the upper normal range by week 6 to 8 in most responders. A 2003 dose-finding study of sermorelin in adults with partial GH deficiency (N=60) found mean IGF-1 increased by 87 ng/mL (approximately 45% from baseline) at 8 weeks on 500 mcg nightly [11]. Patients commonly report reduced post-exertional crashes and improved word retrieval by this timepoint.

Weeks 8 to 16: Immune and Body Composition Shifts

Natural killer cell activity and lymphocyte proliferation may improve as IGF-1 stabilizes. Body composition changes, specifically reduced visceral fat and modestly increased lean mass, become measurable by DEXA scan between months 3 and 4. The landmark Rudman et al. Study (N=21, NEJM 1990) demonstrated a 14.4% increase in lean body mass and 8.8% decrease in adipose tissue over 6 months of GH axis stimulation [12], establishing the mechanistic proof of principle even though the subjects were healthy elderly men rather than PASC patients.

Month 6 and Beyond: Sustained Recovery vs. Cycling

At month 6, reassess IGF-1 and symptom scores. Options are:

1. Discontinue if IGF-1 is in the upper normal range and symptoms have resolved. Re-test IGF-1 at 3 months off peptide.
2. Continue maintenance dosing (200 to 300 mcg, 5 days on / 2 days off) if partial response with ongoing PASC burden.
3. Cycle with 4 to 6 weeks off, then repeat, to preserve pituitary sensitivity.

Evidence Quality Summary

A direct statement about what the evidence does and does not support is appropriate here.

| Claim | Evidence Level | Best Supporting Source | |---|---|---| | GHRH stimulation raises IGF-1 in adults | Level I (RCT data) | Thorner et al., NEJM 1997 [13] | | Low IGF-1 correlates with fatigue and cognitive impairment | Level II (prospective cohort) | Johansson et al., JCEM 2004 [14] | | Pituitary dysfunction after COVID-19 | Level III (case series / cross-sectional) | Frara et al., JCEM 2021 [3] | | Sermorelin specifically for PASC | Level V (expert opinion / framework) | No completed RCT as of 2025 | | GH axis restoration improves body composition | Level I (RCT) | Rudman et al., NEJM 1990 [12] |

The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in Adults states: "We recommend GH therapy for adults with GH deficiency to improve body composition, exercise capacity, skeletal integrity, quality of life, and metabolic profile" [15]. While PASC-associated functional GH insufficiency is not yet a named indication in that guideline, the mechanistic rationale for treatment is grounded in the same physiology.

Safety, Contraindications, and Side-Effect Management

Sermorelin works through physiological amplification, not pharmacological override, which limits the severity of side effects. Still, several concerns require active management.

Common Side Effects

• Injection-site reactions (redness, mild swelling): occur in roughly 15 to 20% of patients; rotate sites and consider insulin pen needles.
• Water retention / facial puffiness: usually dose-dependent; reduce by 100 mcg if persistent beyond 2 weeks.
• Flushing and headache: typically resolve within the first 2 weeks as the GH axis recalibrates.
• Morning grogginess: a sign the dose may be too high or that it is being given too late at night; move injection to 1 hour before sleep rather than immediately before.

Absolute Contraindications

• Active malignancy or history of malignancy within 5 years (IGF-1 is mitogenic)
• Pregnancy or breastfeeding
• Uncontrolled intracranial hypertension
• Allergy to sermorelin or mannitol (preservative in some formulations)

Drug Interactions

Glucocorticoids, especially doses above the physiological replacement range, blunt the pituitary response to sermorelin and may make the peptide ineffective. Insulin and oral hypoglycemics may require dose adjustment if fasting glucose rises more than 20 mg/dL from baseline. Thyroid hormone replacement should be optimized before starting, since hypothyroidism independently reduces GH pulse amplitude [6].

A Note on Regulatory Status

Sermorelin acetate was FDA-approved under the brand name Geref for GH deficiency diagnosis and pediatric GH deficiency treatment. Geref was withdrawn from the US market in 2008 for commercial, not safety, reasons. Compounded sermorelin from 503A pharmacies remains in active clinical use under prescriber authority. The FDA's compounding guidance does not list sermorelin on its list of drugs that may not be compounded; practitioners should verify current status with their compounding pharmacy and their state medical board before prescribing [16].